Antibody-medication conjugates : an interview with Dr Marco Timmers, CSO at Synthon Biopharmaceuticals Interview conducted by April Cashin-Garbutt, BA Hons What are antibody-medication conjugates and what are they used for? ADCs are used for a new kind of targeted therapy that consists of a specific anti-malignancy antibody or antibody fragment linked to a potent anti-tumor therapeutic. Our ADCs deliver deactivated cytotoxins to a cancers cell specifically. Once in the tumor cell, the cytotoxins are released from the ADC, regaining their full cytotoxic activity, leading to rapid cell death pde-5 .
These data are published in the current edition of PNAS in an article entitled ‘Wnt Pathway Inhibition via the Targeting of Frizzled Receptors Results in Decreased Growth and Tumorigenicity of Individual Tumors.’ OMP-18R5 was made using MorphoSys’s proprietary HuCAL GOLD antibody technology. The ongoing Phase 1 trial has been conducted in patients with advanced solid tumors and is designed to assess protection and pharmacokinetics, also to provide preliminary indications of anti-tumor efficacy and the effects of OMP-18R5 on Wnt pathway biomarkers. OMP-18R5 is usually component of OncoMed’s collaboration with Bayer Pharma AG.. Anti-cancer tumor activity of HuCAL antibody revealed by new data from OncoMed MorphoSys AG’s partner OncoMed Pharmaceuticals today announced that Proceedings of the National Academy of Sciences of america of America offers published on the web data demonstrating the powerful anti-tumor activity of OMP-18R5, a HuCAL antibody targeting the Wnt pathway, in multiple preclinical individual tumor models.